Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data)

Anthony A Bavry; Dharam J Kumbhani; Thomas J Helton; Deepak L Bhatt

doi:10.1016/j.amjcard.2005.02.015

Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data)

Am J Cardiol. 2005 Jun 15;95(12):1469-72. doi: 10.1016/j.amjcard.2005.02.015.

Authors

Anthony A Bavry¹, Dharam J Kumbhani, Thomas J Helton, Deepak L Bhatt

Affiliation

¹ Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.

PMID: 15950574
DOI: 10.1016/j.amjcard.2005.02.015

Abstract

We conducted a meta-analysis on 6 studies in 2,963 patients who had coronary artery disease and received a sirolimus-eluting stent or a bare metal stent for revascularization. Compared with bare metal stents, sirolimus-eluting stents did not appear to increase the risk for thrombosis up to 13.5 months after coronary intervention (risk ratio 0.49, 95% confidence interval 0.22 to 1.12, p = 0.09).

Publication types

Comparative Study
Meta-Analysis

MeSH terms

Angioplasty, Balloon, Coronary / instrumentation*
Coated Materials, Biocompatible*
Coronary Disease
Coronary Stenosis / diagnostic imaging
Coronary Stenosis / therapy
Coronary Thrombosis / chemically induced*
Coronary Thrombosis / diagnostic imaging
Coronary Thrombosis / prevention & control
Follow-Up Studies
Humans
Immunosuppressive Agents / adverse effects*
Immunosuppressive Agents / therapeutic use
Incidence
Postoperative Complications
Radiography
Randomized Controlled Trials as Topic
Registries
Retrospective Studies
Risk Factors
Sirolimus / adverse effects*
Sirolimus / therapeutic use
Stents* / adverse effects
Time Factors
Treatment Outcome

Substances

Coated Materials, Biocompatible
Immunosuppressive Agents
Sirolimus